AbbVie Stemcentrx LLC

16 patents currently held · Updated Nov 15, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Feb 2032

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due May 3, 2027
The maintenance fee for Anti-DLL3 antibody drug conjugates (US 9,173,959) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
1 fee due Nov 10, 2027
The maintenance fee for Multivalent DLL3 antibodies (US 9,334,318) comes due Nov 10, 2027. Unpaid by May 10, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 9,534,058	Anti-CD324 monoclonal antibodies and uses thereof In force Term ends Feb 8, 2032 · From the USPTO record	In force	Term ends Feb 8, 2032	From the USPTO record
US 10,087,258	Anti-CD324 monoclonal antibodies and uses thereof In force Term ends Feb 9, 2032 · From the USPTO record	In force	Term ends Feb 9, 2032	From the USPTO record
US 9,409,995	PTK7 modulators and methods of use In force Term ends Feb 17, 2032 · From the USPTO record	In force	Term ends Feb 17, 2032	From the USPTO record
US 10,836,831	Anti-PTK7 antibodies and methods of use In force Term ends Sep 3, 2032 · From the USPTO record	In force	Term ends Sep 3, 2032	From the USPTO record
US 9,458,231	Modulators and methods of use In force Term ends Oct 9, 2032 · From the USPTO record	In force	Term ends Oct 9, 2032	From the USPTO record
US 8,986,972	Nucleic Acid Encoding DLL3 Antibodies In force Term ends Feb 22, 2033 · Medium confidence	In force	Term ends Feb 22, 2033	Medium confidence
US 9,173,959	Anti-DLL3 antibody drug conjugates In force Ends no later than Feb 22, 2033 · From the USPTO record	In force	Ends no later than Feb 22, 2033	From the USPTO record
US 9,334,318	Multivalent DLL3 antibodies In force Ends no later than Feb 22, 2033 · From the USPTO record	In force	Ends no later than Feb 22, 2033	From the USPTO record
US 9,676,850	Anti SEZ6 antibodies and methods of use In force Term ends Feb 22, 2033 · From the USPTO record	In force	Term ends Feb 22, 2033	From the USPTO record
US 11,033,634	Light chain variable regions In force Term ends Feb 22, 2033 · From the USPTO record	In force	Term ends Feb 22, 2033	From the USPTO record

10 of 16 patents shown.

Pro members see all 16.

Pro members: see all 16 patents

Also on record, not counted in the 16: 41 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 abandoned · 26 no status recorded

List them